Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 40.79% since last year same period to $325.72Mn in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 22.98% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 77.12% since last year same period to $165.16Mn in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 39.85% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 25.81% since last year same period to 50.71% in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 13.72% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.61 - a 56.31% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.61.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 46.15% since last year same period to 1.33 in the Q2 2025. This indicates that the Halozyme Therapeutics, Inc. has generated 46.15% annual rate of jump in its earning per share (EPS) in the last 4 quarters.